Market Place
Sourcing Support
Argenx Advance Efgartigimod SC in Idiopathic Inflammatory Myopathy
20 Nov 2024 //
GLOBENEWSWIRE
Argenx Publishes Adhere Study Data In The Lancet Neurology
19 Sep 2024 //
GLOBENEWSWIRE
Zai Lab Announces Second Quarter 2024 Financial Results and Corporate Updates
06 Aug 2024 //
BUSINESSWIRE
Argenx Reports H1 2024 Financials And Q2 Business Update
24 Jul 2024 //
GLOBENEWSWIRE
Argenx `s Biologic Vyvgart (Efgartigimod) Receives Suppl Approvals in US
24 Jul 2024 //
FDA
Zai Lab And Argenx Get China Approval For Efgartigimod In Myasthenia Gravis
16 Jul 2024 //
BUSINESSWIRE
Argenx Highlights Autoimmune Pipeline with New Multifocal Motor Neuropathy Data
25 Jun 2024 //
GLOBENEWSWIRE
Argenx snares 2nd US nod for Vyvgart Hytrulo
22 Jun 2024 //
FIERCE PHARMA
Zai Lab Gets China Priority Review For Efgartigimod CIDP Submission
14 May 2024 //
BUSINESSWIRE
Argenx isn`t sweating over Vyvgart competitors: exec
10 May 2024 //
FIERCE PHARMA
Zai Lab: Q1 2024 Financial Results, Corporate Updates
08 May 2024 //
BUSINESSWIRE
Argenx gears up to launch Vyvgart in next potential indication
17 Apr 2024 //
FIERCE PHARMA
argenx Advances Clinical Development of Efgartigimod in Sjogren`s Disease
27 Mar 2024 //
GLOBENEWSWIRE
FUJIFILM Diosynth Expands Manufacturing Agreement with Argenx for Efgartigimod
25 Mar 2024 //
PRESS RELEASE
Halozyme Announces argenx Received Approval in Japan for VYVDURA
18 Jan 2024 //
PR NEWSWIRE
argenx Announces Approval of VYVDURA Injection for Generalized Myasthenia Gravis
18 Jan 2024 //
GLOBENEWSWIRE
Argenx reports another swing and miss for Vyvgart Hytrulo
20 Dec 2023 //
FIERCE PHARMA
argenx Reports Topline Results from ADDRESS Study of Efgartigimod in Pemphigus
19 Dec 2023 //
GLOBENEWSWIRE
Argenx`s Biologic Vyvgart (efgartigimod) Receives Approval in the U.S.
12 Dec 2023 //
FDA
Zai Lab Announces the First Listing of VYVGART and Other Updates
12 Dec 2023 //
BUSINESSWIRE
Argenx`s Vyvgart comes up short of placebo in ITP trial
28 Nov 2023 //
FIERCE PHARMA
argenx drug Vyvgart fails PhIII study in autoimmune platelet disease
27 Nov 2023 //
ENDPTS
argenx Announces European Commission Approval of Subcutaneous VYVGART
16 Nov 2023 //
GLOBENEWSWIRE
Subcutaneous Vyvgart helps Argenx treat a `broader population`
01 Nov 2023 //
FIERCE PHARMA
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod
15 Sep 2023 //
GLOBENEWSWIRE
Vyvgart shines in CIDP study, teeing up potential nod for Argenx`s pipeline
17 Jul 2023 //
FIERCE PHARMA
Positive Topline Data Reported from argenx`s ADHERE Study of VYVGART® Hytrulo
17 Jul 2023 //
PRESS RELEASE
Argenx: Shares Look Undervalued Ahead of Key Vyvgart Data Readouts
14 Jul 2023 //
MORNINGSTAR
FDA Approves First Subcutaneous Injectable for Muscle-Weakening Disease
22 Jun 2023 //
BIOSPACE
Halozyme Announces argenx Receives FDA Approval for VYVGART®
20 Jun 2023 //
PR NEWSWIRE
Proof-of-concept efgartigimod trial for AAV expected this year
08 May 2023 //
PRESS RELEASE
Argenx Announces UK MHRA Approval of VYVGART for Myasthenia Gravis
16 Mar 2023 //
BIOSPACE
FDA extends review of argenx`s subcutaneous efgartigimod
01 Feb 2023 //
FIERCE PHARMA
Argenx to Present Trial Data During ASH Plenary Session Highlighting VYVGART
10 Dec 2022 //
GLOBENEWSWIRE
Argenx`s Vyvgart (nirmatrelvir) Receives Approval in the Europe
22 Nov 2022 //
EMA
FUJIFILM enters into an Agreement with Argenx to Manufacture Efgartigimod
27 Oct 2022 //
PRESS RELEASE
Argenx`s Vyvgart (efgartigimod alfa) Receives Approval in Europe
26 Sep 2022 //
EMA
Argenx files for FDA approval of subcutaneous efgartigimod
26 Sep 2022 //
FIERCEPHARMA
argenx Submits Biologics License Application to U.S for Sub Efgartigimod
20 Sep 2022 //
GLOBENEWSWIRE
Argenx`s Vyvgart and Alexion`s Ultomiris Go Toe-to-Toe in Myasthenia Gravis
24 Aug 2022 //
PRNEWSWIRE
argenx Announces European Commission Approval of VYVGART™
11 Aug 2022 //
GLOBENEWSWIRE
argenx Receives Positive CHMP Opinion for Efgartigimod in Generalized MG
23 Jun 2022 //
GLOBENEWSWIRE
Medison Pharma Announces Multi-Regional Partnership Agreement with argenx
06 Jun 2022 //
PRNEWSWIRE
Positive Topline Results from ADAPT-SC Study of Subcutaneous Efgartigimod
22 Mar 2022 //
PRNEWSWIRE
argenx Shows +ve Phase 3 Data From ADAPT-SC Study in Subcutaneous Efgartigimod
22 Mar 2022 //
BUSINESSWIRE
IQVIA, Argenx Partner to Accelerate Clinical Development of VYVGART
01 Mar 2022 //
CONTRACTPHARMA
Soleo Health Selected as Limited Distribution Partner for VYVGART™
24 Jan 2022 //
BUSINESSWIRE
Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease
21 Dec 2021 //
LABIOTEC
With its first FDA approval in hand, Argenx is primed to launch
18 Dec 2021 //
FIERCEPHARMA
Argenx`s Biologic Vyvgart (Efgartigimod Alfa) Receives Approval in the U.S.
17 Dec 2021 //
FDA
FDA Approves New Treatment for Myasthenia Gravis
17 Dec 2021 //
FDA
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod
16 Jun 2021 //
GLOBENEWSWIRE
argenx Announces FDA Acceptance of BLA Filing for Efgartigimod
02 Mar 2021 //
GLOBENEWSWIRE
